Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Clinical Trials

Clinical Trials at The Methodist Hospital Research Institute

Search results...

Gland and Hormone Related Diseases

Active and enrolling clinical trials for Gland and Hormone Related Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Breast Cancers

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)

CAT Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast canc...(read more)

Denosumab - Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:Purpose: This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therap...(read more)

Ganetespib STA-9090 for Metastatic HER2 Positive or Triple Negative Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment ...(read more)

ICE Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer (MBC) after failing an anthracycline and a taxane regimen. Cetuximab is acti...(read more)

Katherine, B50, for Treatment of Adjuvant HER2 Positive Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have res...(read more)

M12-895 Abbott Phase II
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The Study Evaluating Efficacy And Tolerability of Veliparib in Combination with Temozolomide or Veliparib/Placebo in Combination with Carboplatin and Paclitaxel in Subjects with Breast Cancer Gene (BR...(read more)

NECTAR Everolimus plus Cisplatin in Triple (-) Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:PURPOSE: The purpose of this study is to test how effective combing a Cisplatin chemotherapy with Everolimus is in treating subjects with residual triple negative breast cancer, who have already recei...(read more)

NSABP B43
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or...(read more)

NSABP B47
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination ch...(read more)

Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Study Status: Active/Enrolling
Investigator: Patel, Tejal
Study Coordinator: Bass, Anastasia
Phone: 713-441-8389
Summary:This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is re...(read more)

PREDATOR TRIAL
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:The purpose of this phase II study is to find out if the test, Mammostrat® can be used as a predictor or outcome tool to determine who will best benefit from chemotherapy prior to surgery. This can be...(read more)

PROMIS registry of mammaprint in breast cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:This is a prospective registry study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.(read more)

REP0210: Reparixin in early breast cancer patients prior to surgery
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This is a pilot "window of opportunity" clinical study in patients with operable breast cancer investigating use of reparixin as single agent in the time period between clinical diagnosis and surgery....(read more)

S0812 Vitamin D in High Risk Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenop...(read more)

SWOG 1007
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibit...(read more)

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable dis...(read more)

Triple Negative RAD 001
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everol...(read more)
Cirrhosis

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)

Salix: Rifaximin Soluble Solid Dispersion SSD Tablets for Decompensated Liver Cirrhosis
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or h...(read more)
Diabetes Mellitus

EXSCEL
Study Status: Active/Enrolling
Investigator: Davies, Mark
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular ...(read more)
Hepatitis Infections

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)
Liver Diseases

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)
Liver Transplant

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)
Osteoporosis

P-15 Bone Putty in ACDF
Study Status: Active/Enrolling
Investigator: Baskin, David
Study Coordinator: Resendez, Darla
Phone: 713-441-3803
Summary:The aim of this trial is to evaluate if P-15 bone putty (investigational device) is not inferior in effectiveness and safety to local autologous bone (control device) when applied in instrumented ante...(read more)
Prostate Cancers

LUTS Pilot - VESI-11E02
Study Status: Active/Enrolling
Investigator: Boone, Timothy
Study Coordinator: Whipple, Melissa
Phone: 713-441-3247
Summary:A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 ...(read more)